 |
|
 |
|
|
|
|
|
Home : Advanced Search : Course view :
|
 
| Course: |
New Perspectives in Colorectal Cancer |
| Target Audience: |
This activity has been designed to meet the educational needs of oncologists, oncology fellows, and oncology nurses involved in the care of patients with colorectal cancer.
Program Overview:
Colorectal cancer is the third most common cancer and the third leading cause of cancer mortality in the United States. Until recently, chemotherapy with FOLFOX or FOLFIRI was the mainstay of treatment. However, in the past years, the addition of new biologic agents targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGR) in combination with various chemotherapy regimens has significantly improved progression-free survival and overall survival in patients with this disease. Welcome as these developments are, understanding the new regimens, evaluating ever-increasing clinical data, and incorporating new advances into existing therapeutic strategies, requires considerable time and effort on the part of clinicians if they are to be able to offer their patients the best therapy available.
The purpose of this activity is to provide education on the latest advances in the treatment of colorectal cancer. |
| Sponsor: |
| Jointly sponsored by Postgraduate Institute for Medicine and Medical Dialogues Group.
|
| Accreditation: |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Medical Dialogues Group. PIM is accredited by the ACCME to provide continuing medical education for physicians.
www.pimed.com
|
| Credit Designation: |
| Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| Faculty Listing: |
John L. Marshall, MD
Chief, Division Hematology and Oncology
Director, Development Therapeutics and GI Oncology
Lombardi Cancer Center
Georgetown University |
| Subjects: |
- Oncology, Colorectal Cancer
|
| Objectives: |
- Outline available chemotherapy and chemotherapy/biologic regimens for the treatment of metastatic colorectal cancer in terms of their efficacy, toxicity profiles, and route of administration in determining treatment for individual patients that optimizes outcomes.
- Cite current clinical data on the use of intermittent therapy to reduce side effects of chemotherapy and permit patients to remain on treatment longer.
- Describe the role of biomarkers, particularly the KRAS mutation and microsatellite instability, in choosing appropriate therapy for patients with colorectal cancer.
|
| Financial Disclosure: |
John L. Marshall, MD
Consulting Fees, Non-CME Services, Contracted Research: Amgen, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Pfizer, Inc.; Roche; Sanofi-Aventis
The following PIM planners and managers, Linda Graham, RN, BSN, BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Medical Dialogues Group planners and managers, Rick Rodes and Susan Ruffalo hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
- You are not currently logged in.
- To view content articles and complete the post-test for this course, please login or register now
|
|
|
|
|
